Wen-JenHwuMD

Oncology • Houston, TX

Physician

Join to view full profile

Are you Dr. Hwu?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 63 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6161

Summary

Dr. Wen-Jen Hwu, MD is an oncologist in Houston, Texas. She is currently licensed to practice medicine in Texas, New York, and Connecticut. She is affiliated with University of Texas M.D. Anderson Cancer Center.

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1986 - 1988
University of California (Irvine)Residency, Internal Medicine, 1982 - 1985
University of California, Irvine, School of MedicineClass of 1982

Certifications & Licensure

CA State Medical License 1983 - 2026
TX State Medical License 2005 - 2018
CT State Medical License 1984 - 2009
NY State Medical License 1988 - 2008
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 1999 Dec 01
Completed
Phase 1, Phase 2
Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma Start of enrollment: 2001 May 01
Completed
Phase 2
Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma Start of enrollment: 2003 Jul 01
Completed
Phase 2
Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients Start of enrollment: 2006 Aug 01
Completed
Phase 2
Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion Start of enrollment: 2008 Sep 02
Terminated
Phase 1
Adjuvant Therapy of Pegylated Interferon- 2b Plus Melanoma Peptide Vaccine Start of enrollment: 2009 Mar 10
Completed
Phase 1
High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI Start of enrollment: 2011 Feb 22
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Dual PD-L1/SOX10 Immunohistochemistry Combined With Digital Imaging Enhances Stratification Accuracy of Patients With Metastatic Melanoma.
Juan Pineda-Reyes, Sri Krishna Arudra, Phyu P Aung, Priyadharsini Nagarajan, Jonathan L Curry
The American Journal of Surgical Pathology. 2024-10-07
Apoptosis Pathway-Associated Proteins Are Frequently Expressed in Melanoma: A Study of 32 Cases With Focus on Acral Lentiginous Melanoma.
Debora A Ledesma, Mario L Marques-Piubelli, Elsa Li-Ning-Tapia, Courtney Hudgens, Jun Gu
The American Journal of Dermatopathology. 2024-07-01
6 citations
Prognostic Significance of Subungual Anatomic Site in Acral Lentiginous Melanoma.
Haider A. Mejbel, Carlos A. Torres-Cabala, Denái R. Milton, Doina Ivan, Priyadharsini Nagarajan
Archives of Pathology & Laboratory Medicine. 2021-08-01

Professional Memberships

American Society of Clinical Oncology - ASCO
Member